Table 2 Functional enrichment of the eigenproteins identified in the host response kinetics to VN1203
From: Specific mutations in H5N1 mainly impact the magnitude and velocity of the host response in mice
Eigenprotein (No. of molecules) | Bio functions category (functions annotation p-value range) | Canonical pathway (p-value) | Upstream regulator (p-value of overlap) |
|---|---|---|---|
eigenprotein #1 (59) | Free radical scavenging (8.24E-07–2.56E-02) | NRF2-mediated oxidative stress response (2.40E-05) | D3T* (2.77E-06) |
Drug metabolism (3.50E-05–2.87E-02) | Glutathione-mediated detoxification (2.69E-04) | MAPT (6.72E-06) | |
Auditory disease (6.12E-05–6.12E-05) | G Beta gamma signaling (2.82E-04) | TP53 (8.41E-06) | |
Developmental disorder (1.52E-04–2.56E-02) | Ceramide signaling (2.45E-03) | NFE2L2 (1.40E-05) | |
Hereditary disorder (1.52E-04–6.45E-03) | EIF2 signalin (3.02E-03) | PSEN1 (1.16E-04) | |
eigenprotein #2 (86) | Neurological disease (3.89E-08–8.48E-03) | Acute phase response signaling (1.26E-25) | Nitrofurantoin* (3.03E-12) |
Cell-to-cell signaling and interaction (8.90E-08–1.08E-02) | LXR/RXR Activation (1.58E-13) | Captopril* (1.79E-08) | |
Tissue development (8.90E-08–1.08E-02) | Clathrin-mediated endocytosis signaling (9.77E-08) | IL6 (1.83E-07) | |
Metabolic disease (2.66E-07–1.02E-02) | Complement system (3.02E-07) | Gentamicin* (5.04E-07) | |
Lipid metabolism (5.24E-07–1.17E-02) | Coagulation system (3.55E-07) | T3* (8.12E-07) | |
eigenprotein #3 (17) | Cell death and survival (1.82E-05–4.83E-02) | Breast cancer regulation by Stathmin1 (1.70E-05) | PLG (2.14E-04) |
Hematological system Development and function (9.90E-05–4.48E-02) | Cardiac β-adrenergic signaling (1.91E-04) | APP (1.19E-03) | |
Organismal injury and abnormalities (1.63E-04–4.83E-02) | AMPK signaling (2.24E-04) | PSEN1 (2.06E-03) | |
Tissue morphology (8.38E-04–4.19E-02) | CREB signaling in neurons (4.07E-04) | MAP2 (2.12E-03) | |
|  | Cancer (8.38E-04–4.99E-02) | Role of NFAT in cardiac hypertrophy (4.57E-07) | GNG7 (2.12E-03) |